Hydroxychloroquine רפואה פאר COVID-19

אבינו מלכנו מנע מגיפה מנחלתך - אלעס ארום די קאראנא וויירוס

די אחראים: אחראי, געלעגער

יואל שרייבער
שר האלפיים
תגובות: 2300
זיך איינגעשריבען אום: דינסטאג אפריל 04, 2017 1:33 am

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך יואל שרייבער » מאנטאג יוני 08, 2020 8:59 am

גערעכט , מיי מיסטעיק.

אוועטאר
סטיטשינער
שר עשרת אלפים
תגובות: 13980
זיך איינגעשריבען אום: דאנארשטאג ינואר 05, 2017 3:49 pm
לאקאציע: 50°18′N 21°4′E

תגובהדורך סטיטשינער » מאנטאג יוני 08, 2020 7:12 pm

UK halts trial of hydroxychloroquine as 'useless' for COVID-19 patients



British scientists halted a major drug trial on Friday after it found that the anti-malarial hydroxychloroquine, touted by U.S. President Donald Trump as a potential “game-changer” in the pandemic, was “useless” at treating COVID-19 patients.

“This is not a treatment for COVID-19. It doesn’t work,” Martin Landray, an Oxford University professor who is co-leading the RECOVERY trial, told reporters.

“This result should change medical practice worldwide. We can now stop using a drug that is useless.”

Vocal support from Trump raised expectations for the decades-old drug that experts said could have been a cheap and widely available tool, if proven to work, in fighting the pandemic, which has infected more than 6.4 million people and killed nearly 400,000 worldwide.

The controversy surrounding the drug grew after a study published in the medical journal The Lancet last month raised safety concerns and led several COVID-19 studies of it to be halted. The Lancet study was then retracted on Thursday after its authors said they were unsure about its data.

Landray, a professor of medicine and epidemiology at Oxford University, noted the “huge speculation” about the drug as a treatment for COVID-19 but said there had been until now “an absence of reliable information from large randomized trials”.

He said the preliminary results from RECOVERY, which was a randomized trial, we're now quite clear: hydroxychloroquine does not reduce the risk of death among hospitalized patients with COVID-19.

“If you’re admitted to hospital, don’t take hydroxychloroquine,” he said.

Source Reuters
והעיקר, די מיני הערות זענען מיינע גרינע, דהיינו איך האב געליינט, און איך האב עס אפי' אפגעלערנט


מצפים לישועה
שר האלף
תגובות: 1244
זיך איינגעשריבען אום: זונטאג אוקטובער 15, 2017 2:49 pm

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך מצפים לישועה » דינסטאג יוני 09, 2020 3:50 pm


מצפים לישועה
שר האלף
תגובות: 1244
זיך איינגעשריבען אום: זונטאג אוקטובער 15, 2017 2:49 pm

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך מצפים לישועה » דאנארשטאג יוני 11, 2020 3:49 pm


קלוגע חכם
שר חמישים ומאתים
תגובות: 340
זיך איינגעשריבען אום: מיטוואך אוגוסט 20, 2014 8:43 am

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך קלוגע חכם » מאנטאג יוני 15, 2020 5:01 pm

ווי
לעצט פאראכטן דורך קלוגע חכם אום מיטוואך יוני 17, 2020 3:00 pm, מאל פאראכטן געווארן 1 סך הכל.

געוואלטיג
שר האלף
תגובות: 1203
זיך איינגעשריבען אום: מאנטאג אוגוסט 29, 2011 5:12 pm

Re: Re:

תגובהדורך געוואלטיג » מאנטאג יוני 15, 2020 6:35 pm

לעבט אין לאכט האט געשריבן:
סטיטשינער האט געשריבן:ממש פורים דארט.

גא"מ
די פראבלעם איז אז עס איז "דא" אין אז די אלע פאליטישע און בויקראטישע שפילירייען אפעקטירן אידישע אין להבדיל סתם מענטשליכע לעבן'ס
א בראך פאר אזא פורים


יעדע מעדישקעישאן האט סייד עפעקטס און מדארף שוקל זיין שכרה כנגד הפסידה
די ווייטאג איז נאר אז די פאליטיק איז די גורם צו מזאל פארגרעסערן די הפסד אדער די שכר וואס מיינט אז אנשטאט די פאקטן זאלן פסקענען פסקענט די פאליטיק אויף לעבן פון מענטשן

אוועטאר
לעבט אין לאכט
שר מאה
תגובות: 129
זיך איינגעשריבען אום: מיטוואך ינואר 13, 2016 10:20 pm

Re: Re:

תגובהדורך לעבט אין לאכט » דינסטאג יוני 16, 2020 11:23 am

געוואלטיג האט געשריבן:
לעבט אין לאכט האט געשריבן:
סטיטשינער האט געשריבן:ממש פורים דארט.

גא"מ
די פראבלעם איז אז עס איז "דא" אין אז די אלע פאליטישע און בויקראטישע שפילירייען אפעקטירן אידישע אין להבדיל סתם מענטשליכע לעבן'ס
א בראך פאר אזא פורים


יעדע מעדישקעישאן האט סייד עפעקטס און מדארף שוקל זיין שכרה כנגד הפסידה
די ווייטאג איז נאר אז די פאליטיק איז די גורם צו מזאל פארגרעסערן די הפסד אדער די שכר וואס מיינט אז אנשטאט די פאקטן זאלן פסקענען פסקענט די פאליטיק אויף לעבן פון מענטשן

I agree
אט דאס איז מיין פוינט
אז מען לאכט לעבט מען

מצפים לישועה
שר האלף
תגובות: 1244
זיך איינגעשריבען אום: זונטאג אוקטובער 15, 2017 2:49 pm

Re: Re:

תגובהדורך מצפים לישועה » מיטוואך יוני 17, 2020 6:53 pm

געוואלטיג האט געשריבן:
לעבט אין לאכט האט געשריבן:
סטיטשינער האט געשריבן:ממש פורים דארט.

גא"מ
די פראבלעם איז אז עס איז "דא" אין אז די אלע פאליטישע און בויקראטישע שפילירייען אפעקטירן אידישע אין להבדיל סתם מענטשליכע לעבן'ס
א בראך פאר אזא פורים


יעדע מעדישקעישאן האט סייד עפעקטס און מדארף שוקל זיין שכרה כנגד הפסידה
די ווייטאג איז נאר אז די פאליטיק איז די גורם צו מזאל פארגרעסערן די הפסד אדער די שכר וואס מיינט אז אנשטאט די פאקטן זאלן פסקענען פסקענט די פאליטיק אויף לעבן פון מענטשן

די עיקר סיידעפעקט פון קלאראקווין ווען מען נעמט דאס און אנפאנג איז אז דאס וועט גורם זיין אז ווייניגער מענטשן וועלן נעמען דעם וועקסין.

אוועטאר
מחשב
שר שלשת אלפים
תגובות: 3361
זיך איינגעשריבען אום: דינסטאג יולי 17, 2018 3:57 pm

Re: Re:

תגובהדורך מחשב » מיטוואך יוני 17, 2020 11:38 pm

מצפים לישועה האט געשריבן:
געוואלטיג האט געשריבן:
לעבט אין לאכט האט געשריבן:
סטיטשינער האט געשריבן:ממש פורים דארט.

גא"מ
די פראבלעם איז אז עס איז "דא" אין אז די אלע פאליטישע און בויקראטישע שפילירייען אפעקטירן אידישע אין להבדיל סתם מענטשליכע לעבן'ס
א בראך פאר אזא פורים


יעדע מעדישקעישאן האט סייד עפעקטס און מדארף שוקל זיין שכרה כנגד הפסידה
די ווייטאג איז נאר אז די פאליטיק איז די גורם צו מזאל פארגרעסערן די הפסד אדער די שכר וואס מיינט אז אנשטאט די פאקטן זאלן פסקענען פסקענט די פאליטיק אויף לעבן פון מענטשן

די עיקר סיידעפעקט פון קלאראקווין ווען מען נעמט דאס און אנפאנג איז אז דאס וועט גורם זיין אז ווייניגער מענטשן וועלן נעמען דעם וועקסין.

וואס מ'דארף האבן פאר דיפאפיולעישן...

פיר אויס...

נאך איינער
שר חמש מאות
תגובות: 981
זיך איינגעשריבען אום: מאנטאג אפריל 13, 2015 1:15 pm

Re: Re:

תגובהדורך נאך איינער » מיטוואך יוני 17, 2020 11:46 pm

מצפים לישועה האט געשריבן:
געוואלטיג האט געשריבן:
לעבט אין לאכט האט געשריבן:
סטיטשינער האט געשריבן:ממש פורים דארט.

גא"מ
די פראבלעם איז אז עס איז "דא" אין אז די אלע פאליטישע און בויקראטישע שפילירייען אפעקטירן אידישע אין להבדיל סתם מענטשליכע לעבן'ס
א בראך פאר אזא פורים


יעדע מעדישקעישאן האט סייד עפעקטס און מדארף שוקל זיין שכרה כנגד הפסידה
די ווייטאג איז נאר אז די פאליטיק איז די גורם צו מזאל פארגרעסערן די הפסד אדער די שכר וואס מיינט אז אנשטאט די פאקטן זאלן פסקענען פסקענט די פאליטיק אויף לעבן פון מענטשן

די עיקר סיידעפעקט פון קלאראקווין ווען מען נעמט דאס און אנפאנג איז אז דאס וועט גורם זיין אז ווייניגער מענטשן וועלן נעמען דעם וועקסין.

ממעג נאך נעמען קלאראקווין? געהערט זאגן אז מלייגט שוין אויך אריין די טשיפ וואס מגייט אריינלייגן אין די וואקסין,

אוועטאר
בוחר בשירי זמרה
שר האלף
תגובות: 1858
זיך איינגעשריבען אום: דינסטאג ינואר 26, 2016 10:49 pm

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך בוחר בשירי זמרה » פרייטאג יוני 19, 2020 11:50 am

ווי עס זעט אויס איז די סטאדי דיזיינד געווארן אז זיי געבן 3 אדער 4 מאל מער ווי די ערלויבטע דאזעס

וויאזוי קען מען עס איבערלעבן?

דר זעלענקא און אנדערע האבן געגעבן 600 מג

דא האט מען געגעבן צווישן 2 און 4 מאל אזויפיל

כמדומה אז די צוריקצי פון fda איז אויך געבויעט אויף ריזיגע סכנה'דיע דאזעס
https://www.ageofautism.com/2020/06/who ... doses.html

KMW
שר האלף
תגובות: 1650
זיך איינגעשריבען אום: דאנארשטאג פאברואר 23, 2017 11:05 am

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך KMW » פרייטאג יוני 19, 2020 11:55 am

בוחר בשירי זמרה האט געשריבן:ווי עס זעט אויס איז די סטאדי דיזיינד געווארן אז זיי געבן 3 אדער 4 מאל מער ווי די ערלויבטע דאזעס

וויאזוי קען מען עס איבערלעבן?

דר זעלענקא און אנדערע האבן געגעבן 600 מג

דא האט מען געגעבן צווישן 2 און 4 מאל אזויפיל

כמדומה אז די צוריקצי פון fda איז אויך געבויעט אויף ריזיגע סכנה'דיע דאזעס
https://www.ageofautism.com/2020/06/who ... doses.html

א קאנספיראציע סייט נישט באגלײבט.

KMW
שר האלף
תגובות: 1650
זיך איינגעשריבען אום: דאנארשטאג פאברואר 23, 2017 11:05 am

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך KMW » מיטוואך יולי 01, 2020 3:08 pm

hydro1111.JPG
hydro1111.JPG (29.48 KiB) געזעהן 2327 מאל


https://www.yiddish24.com/news/57/21475


מקבל
שר חמישים ומאתים
תגובות: 254
זיך איינגעשריבען אום: מאנטאג ינואר 13, 2014 6:26 pm

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך מקבל » פרייטאג יולי 03, 2020 2:13 pm

דר. זעלענקא אינטערוויוו:
https://www.dropbox.com/s/q3te7z6a2gtss ... 2.mp4?dl=0

איך האב ארויסגעשניטן עטליכע פלעצער ווי עס איז געווען נשים, עס קען פעלן אביסל פון די המשך.
לעצט פאראכטן דורך מקבל אום זונטאג יולי 05, 2020 7:05 pm, מאל פאראכטן געווארן 1 סך הכל.

ירנן
שר חמישים ומאתים
תגובות: 279
זיך איינגעשריבען אום: פרייטאג אוגוסט 23, 2019 3:52 pm

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך ירנן » פרייטאג יולי 03, 2020 4:05 pm

ער שלאגט פאר https://www.koshervitamins.com/Solgar-K ... e-Capsules
אויב מען האט נישט Hydroxychloroquine

נא_שכל
שר חמשת אלפים
תגובות: 5801
זיך איינגעשריבען אום: מאנטאג יולי 14, 2008 10:44 pm
לאקאציע: עולם הדמיון

מלאך רע בעל כרחך יענה...

תגובהדורך נא_שכל » זונטאג יולי 05, 2020 3:40 pm

אין זייער סופרייזינג נייעס האט סי. ען. ען. געמאלדען אז די מעדיצין האט געהאלפען פאר זייער אסאך חולים אין שפיטאל, אבער... ריסערטשערס האבן ספיקות...

Study finds hydroxychloroquine may have boosted survival, but other researchers have doubts

By Maggie Fox, Andrea Kane, and Elizabeth Cohen, CNN

Updated 1731 GMT (0131 HKT) July 3, 2020

(CNN)A surprising new study found the controversial antimalarial drug hydroxychloroquine helped patients better survive in the hospital. But the findings, like the federal government's use of the drug itself, were disputed.

A team at Henry Ford Health System in southeast Michigan said Thursday their study of 2,541 hospitalized patients found that those given hydroxychloroquine were much less likely to die.
Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System, said 26% of those not given hydroxychloroquine died, compared to 13% of those who got the drug. The team looked back at everyone treated in the hospital system since the first patient in March.

"Overall crude mortality rates were 18.1% in the entire cohort, 13.5% in the hydroxychloroquine alone group, 20.1% among those receiving hydroxychloroquine plus azithromycin, 22.4% among the azithromycin alone group, and 26.4% for neither drug," the team wrote in a report published in the International Journal of Infectious Diseases.

It's a surprising finding because several other studies have found no benefit from hydroxychloroquine, a drug originally developed to treat and prevent malaria. President Donald Trump touted the drug heavily, but later studies found not only did patients not do better if they got the drug, they were more likely to suffer cardiac side effects.

The US Food and Drug Administration withdrew its emergency use authorization for the drug earlier this month and trials around the world, including trials sponsored by the World Health Organization and the National Institutes of Health, were halted.
Researchers not involved in the Henry Ford study pointed out it wasn't of the same quality of the studies showing hydroxychloroquine did not help patients, and said other treatments, such as the use of the steroid dexamethasone, might have accounted for the better survival of some patients.

"Our results do differ from some other studies," Zervos told a news conference. "What we think was important in ours ... is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with Covid," he added.

The Henry Ford team also monitored patients carefully for heart problems, he said.
"The combination of hydroxychloroquine plus azithromycin was reserved for selected patients with severe COVID-19 and with minimal cardiac risk factors," the team wrote.
The Henry Ford team said they believe their findings show hydroxychloroquine could be potentially useful as a treatment for coronavirus.
"It's important to note that in the right settings, this potentially could be a lifesaver for patients," Dr. Steven Kalkanis, CEO of the Henry Ford Medical Group, said at the news conference.

Kalkanis said that their findings do not necessarily contradict those of earlier studies. "We also want to make the point that just because our results differ from some others that may have been published, it doesn't make those studies wrong or definitely a conflict. What it simply means is that by looking at the nuanced data of which patients actually benefited and when, we might be able to further unlock the code of how this disease works," he said.
"Much more work needs to be done to elucidate what the final treatment plan should be for Covid-19," Kalkanis added. "But we feel ... that these are critically important results to add to the mix of how we move forward if there's a second surge, and in relevant other parts of the world. Now we can help people combat this disease and to reduce the mortality rate."
Zervos said hydroxychloroquine can help interfere with the virus directly and also reduces inflammation.

Researchers not involved with the study were critical. They noted that the Henry Ford team did not randomly treat patients but selected them for various treatments based on certain criteria.
"As the Henry Ford Health System became more experienced in treating patients with COVID-19, survival may have improved, regardless of the use of specific therapies," Dr. Todd Lee of the Royal Victoria Hospital in Montreal, Canada, and colleagues wrote in a commentary in the same journal.
"Finally, concomitant steroid use in patients receiving hydroxychloroquine was more than double the non-treated group. This is relevant considering the recent RECOVERY trial that showed a mortality benefit with dexamethasone." The steroid dexamethasone can reduce inflammation in seriously ill patients.

The Henry Ford team wrote that 82% of their patients received hydroxychloroquine within the first 24 hours of admission, and 91% within the first 48 hours of admission.
They wrote that in comparison, a study of patients at 25 New York hospitals started taking the drug "at any time during their hospitalization."
But patients in that New York study, published in May in the Journal of the American Medical Association, started taking hydroxychloroquine on average one day after being hospitalized.
"Maybe there's a little bit of a difference, but it's not like patients in New York were being started on day seven. That's not what happened," said Eli Rosenberg, lead author of the New York study and an associate professor of epidemiology at the University at Albany School of Public Health.

Rosenberg also pointed out that the Detroit paper excluded 267 patients -- nearly 10% of the study population -- who had not yet been discharged from the hospital.
He said this might have skewed the results to make hydroxychloroquine look better than it really was. Those patients might have still been in the hospital because they were very sick, and if they died, excluding them from the study made hydroxychloroquine look like more of a lifesaver than it really was.
"There's a little bit of loosey-goosiness here in all this," he told CNN.
Both the Detroit and New York studies were observational: they looked back at how patients did when doctors prescribed hydroxychloroquine.
While helpful, observational studies are not as valuable as controlled clinical trials. Considered the gold standard in medicine, patients in a clinical trial are randomly assigned to take either the drug or a placebo, which is a treatment that does nothing. Doctors then follow the patients to see how they fare.
Two clinical trials on hydroxychloroquine for Covid-19, one in the US and one in the UK, were stopped early because their data suggested hydroxychloroquine wasn't helpful.

The US trial, run by the National Institutes of Health, enrolled more than 470 patients.
The UK trial, run by the University of Oxford, enrolled more than 11,000 patients.
"We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalized with COVID-19," the Oxford doctors concluded.

But a White House official praised the Henry Ford team's study.

Peter Navarro, the White House trade adviser, said the study shows hydroxychloroquine works if given early enough.
"This is a big deal," he told CNN. "This medicine can literally save tens of thousands, perhaps hundreds of thousands of American lives and maybe millions of people worldwide."
"ואומר לאשר יבוא מכתבי לחזות, אכול את המגילה הזאת. כי מהאוכל יצא מאכל, ושכל יצא משכל ..." (ר' ברכיה בן נטרונאי הנקדן, בהקדמת ספרו 'משלי שועלים').

לא לנו
שר האלף
תגובות: 1798
זיך איינגעשריבען אום: דינסטאג מארטש 10, 2015 12:16 pm

Re: מלאך רע בעל כרחך יענה...

תגובהדורך לא לנו » זונטאג יולי 05, 2020 3:54 pm

נא_שכל האט געשריבן:אין זייער סופרייזינג נייעס האט סי. ען. ען. געמאלדען אז די מעדיצין האט געהאלפען פאר זייער אסאך חולים אין שפיטאל, אבער... ריסערטשערס האבן ספיקות...

Study finds hydroxychloroquine may have boosted survival, but other researchers have doubts

By Maggie Fox, Andrea Kane, and Elizabeth Cohen, CNN

Updated 1731 GMT (0131 HKT) July 3, 2020

(CNN)A surprising new study found the controversial antimalarial drug hydroxychloroquine helped patients better survive in the hospital. But the findings, like the federal government's use of the drug itself, were disputed.

A team at Henry Ford Health System in southeast Michigan said Thursday their study of 2,541 hospitalized patients found that those given hydroxychloroquine were much less likely to die.
Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System, said 26% of those not given hydroxychloroquine died, compared to 13% of those who got the drug. The team looked back at everyone treated in the hospital system since the first patient in March.

"Overall crude mortality rates were 18.1% in the entire cohort, 13.5% in the hydroxychloroquine alone group, 20.1% among those receiving hydroxychloroquine plus azithromycin, 22.4% among the azithromycin alone group, and 26.4% for neither drug," the team wrote in a report published in the International Journal of Infectious Diseases.

It's a surprising finding because several other studies have found no benefit from hydroxychloroquine, a drug originally developed to treat and prevent malaria. President Donald Trump touted the drug heavily, but later studies found not only did patients not do better if they got the drug, they were more likely to suffer cardiac side effects.

The US Food and Drug Administration withdrew its emergency use authorization for the drug earlier this month and trials around the world, including trials sponsored by the World Health Organization and the National Institutes of Health, were halted.
Researchers not involved in the Henry Ford study pointed out it wasn't of the same quality of the studies showing hydroxychloroquine did not help patients, and said other treatments, such as the use of the steroid dexamethasone, might have accounted for the better survival of some patients.

"Our results do differ from some other studies," Zervos told a news conference. "What we think was important in ours ... is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with Covid," he added.

The Henry Ford team also monitored patients carefully for heart problems, he said.
"The combination of hydroxychloroquine plus azithromycin was reserved for selected patients with severe COVID-19 and with minimal cardiac risk factors," the team wrote.
The Henry Ford team said they believe their findings show hydroxychloroquine could be potentially useful as a treatment for coronavirus.
"It's important to note that in the right settings, this potentially could be a lifesaver for patients," Dr. Steven Kalkanis, CEO of the Henry Ford Medical Group, said at the news conference.

Kalkanis said that their findings do not necessarily contradict those of earlier studies. "We also want to make the point that just because our results differ from some others that may have been published, it doesn't make those studies wrong or definitely a conflict. What it simply means is that by looking at the nuanced data of which patients actually benefited and when, we might be able to further unlock the code of how this disease works," he said.
"Much more work needs to be done to elucidate what the final treatment plan should be for Covid-19," Kalkanis added. "But we feel ... that these are critically important results to add to the mix of how we move forward if there's a second surge, and in relevant other parts of the world. Now we can help people combat this disease and to reduce the mortality rate."
Zervos said hydroxychloroquine can help interfere with the virus directly and also reduces inflammation.

Researchers not involved with the study were critical. They noted that the Henry Ford team did not randomly treat patients but selected them for various treatments based on certain criteria.
"As the Henry Ford Health System became more experienced in treating patients with COVID-19, survival may have improved, regardless of the use of specific therapies," Dr. Todd Lee of the Royal Victoria Hospital in Montreal, Canada, and colleagues wrote in a commentary in the same journal.
"Finally, concomitant steroid use in patients receiving hydroxychloroquine was more than double the non-treated group. This is relevant considering the recent RECOVERY trial that showed a mortality benefit with dexamethasone." The steroid dexamethasone can reduce inflammation in seriously ill patients.

The Henry Ford team wrote that 82% of their patients received hydroxychloroquine within the first 24 hours of admission, and 91% within the first 48 hours of admission.
They wrote that in comparison, a study of patients at 25 New York hospitals started taking the drug "at any time during their hospitalization."
But patients in that New York study, published in May in the Journal of the American Medical Association, started taking hydroxychloroquine on average one day after being hospitalized.
"Maybe there's a little bit of a difference, but it's not like patients in New York were being started on day seven. That's not what happened," said Eli Rosenberg, lead author of the New York study and an associate professor of epidemiology at the University at Albany School of Public Health.

Rosenberg also pointed out that the Detroit paper excluded 267 patients -- nearly 10% of the study population -- who had not yet been discharged from the hospital.
He said this might have skewed the results to make hydroxychloroquine look better than it really was. Those patients might have still been in the hospital because they were very sick, and if they died, excluding them from the study made hydroxychloroquine look like more of a lifesaver than it really was.
"There's a little bit of loosey-goosiness here in all this," he told CNN.
Both the Detroit and New York studies were observational: they looked back at how patients did when doctors prescribed hydroxychloroquine.
While helpful, observational studies are not as valuable as controlled clinical trials. Considered the gold standard in medicine, patients in a clinical trial are randomly assigned to take either the drug or a placebo, which is a treatment that does nothing. Doctors then follow the patients to see how they fare.
Two clinical trials on hydroxychloroquine for Covid-19, one in the US and one in the UK, were stopped early because their data suggested hydroxychloroquine wasn't helpful.

The US trial, run by the National Institutes of Health, enrolled more than 470 patients.
The UK trial, run by the University of Oxford, enrolled more than 11,000 patients.
"We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalized with COVID-19," the Oxford doctors concluded.

But a White House official praised the Henry Ford team's study.

Peter Navarro, the White House trade adviser, said the study shows hydroxychloroquine works if given early enough.
"This is a big deal," he told CNN. "This medicine can literally save tens of thousands, perhaps hundreds of thousands of American lives and maybe millions of people worldwide."

ווער איז דער טיטול-געבער אויף די מלאכים?

KMW
שר האלף
תגובות: 1650
זיך איינגעשריבען אום: דאנארשטאג פאברואר 23, 2017 11:05 am

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך KMW » זונטאג יולי 05, 2020 4:54 pm

זיי גייען אייביג מער שטיצן רעמדעסעוויר וואס קאסט בערך 3000 דאלער פער מענטש

https://www.statnews.com/2020/06/29/gil ... -covid-19/

פארשער
שר האלף
תגובות: 1330
זיך איינגעשריבען אום: מיטוואך דעצמבער 16, 2009 7:20 pm

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך פארשער » זונטאג יולי 12, 2020 2:45 pm

Yossi Gestetner (@YossiGestetner)

A limited study by Mount Sinai released 6/30/20 shows that “hydroxychloroquine use was associated with decreased risk of in-hospital mortality.”
https://link.springer.com/content/pdf/1 ... 5983-z.pdf

Twitter · 12 hours ago

אוועטאר
בוחר בשירי זמרה
שר האלף
תגובות: 1858
זיך איינגעשריבען אום: דינסטאג ינואר 26, 2016 10:49 pm

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך בוחר בשירי זמרה » זונטאג יולי 26, 2020 10:16 pm

א יעיל יוניווערסיטי פראפעסאר האט טענות אויף דאס נישט נוצן היידראקסי קלאריקווין מיט זינק און זיטראמייסין,

טיילווייז צוליב פאליטיק

אפ עד אין ניוזוויק




The Key to Defeating COVID-19 Already Exists. We Need to Start Using It | Opinion


HARVEY A. RISCH, MD, PHD , PROFESSOR OF EPIDEMIOLOGY, YALE SCHOOL OF PUBLIC HEALTH


ON 7/23/20 AT 7:00 AM EDT


As professor of epidemiology at Yale School of Public Health, I have authored over 300 peer-reviewed publications and currently hold senior positions on the editorial boards of several leading journals. I am usually accustomed to advocating for positions within the mainstream of medicine, so have been flummoxed to find that, in the midst of a crisis, I am fighting for a treatment that the data fully support but which, for reasons having nothing to do with a correct understanding of the science, has been pushed to the sidelines. As a result, tens of thousands of patients with COVID-19 are dying unnecessarily. Fortunately, the situation can be reversed easily and quickly.
I am referring, of course, to the medication hydroxychloroquine. When this inexpensive oral medication is given very early in the course of illness, before the virus has had time to multiply beyond control, it has shown to be highly effective, especially when given in combination with the antibiotics azithromycin or doxycycline and the nutritional supplement zinc.
On May 27, I published an article in the American Journal of Epidemiology (AJE) entitled, "Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis." That article, published in the world's leading epidemiology journal, analyzed five studies, demonstrating clear-cut and significant benefits to treated patients, plus other very large studies that showed the medication safety.
Physicians who have been using these medications in the face of widespread skepticism have been truly heroic. They have done what the science shows is best for their patients, often at great personal risk. I myself know of two doctors who have saved the lives of hundreds of patients with these medications, but are now fighting state medical boards to save their licenses and reputations. The cases against them are completely without scientific merit.
Since publication of my May 27 article, seven more studies have demonstrated similar benefit. In a lengthy follow-up letter, also published by AJE, I discuss these seven studies and renew my call for the immediate early use of hydroxychloroquine in high-risk patients. These seven studies include: an additional 400 high-risk patients treated by Dr. Vladimir Zelenko, with zero deaths; four studies totaling almost 500 high-risk patients treated in nursing homes and clinics across the U.S., with no deaths; a controlled trial of more than 700 high-risk patients in Brazil, with significantly reduced risk of hospitalization and two deaths among 334 patients treated with hydroxychloroquine; and another study of 398 matched patients in France, also with significantly reduced hospitalization risk. Since my letter was published, even more doctors have reported to me their completely successful use.
My original article in the AJE is available free online, and I encourage readers—especially physicians, nurses, physician assistants and associates, and respiratory therapists—to search the title and read it. My follow-up letter is linked there to the original paper.
Beyond these studies of individual patients, we have seen what happens in large populations when these drugs are used. These have been "natural experiments." In the northern Brazil state of Pará, COVID-19 deaths were increasing exponentially. On April 6, the public hospital network purchased 75,000 doses of azithromycin and 90,000 doses of hydroxychloroquine. Over the next few weeks, authorities began distributing these medications to infected individuals. Even though new cases continued to occur, on May 22 the death rate started to plummet and is now about one-eighth what it was at the peak.
Hydroxychloroquine tabletsGEORGE FREY/AFP VIA GETTY IMAGES
A reverse natural experiment happened in Switzerland. On May 27, the Swiss national government banned outpatient use of hydroxychloroquine for COVID-19. Around June 10, COVID-19 deaths increased four-fold and remained elevated. On June 11, the Swiss government revoked the ban, and on June 23 the death rate reverted to what it had been beforehand. People who die from COVID-19 live about three to five weeks from the start of symptoms, which makes the evidence of a causal relation in these experiments strong. Both episodes suggest that a combination of hydroxychloroquine and its companion medications reduces mortality and should be immediately adopted as the new standard of care in high-risk patients.
Why has hydroxychloroquine been disregarded?
First, as all know, the medication has become highly politicized. For many, it is viewed as a marker of political identity, on both sides of the political spectrum. Nobody needs me to remind them that this is not how medicine should proceed. We must judge this medication strictly on the science. When doctors graduate from medical school, they formally promise to make the health and life of the patient their first consideration, without biases of race, religion, nationality, social standing—or political affiliation. Lives must come first.
Second, the drug has not been used properly in many studies. Hydroxychloroquine has shown major success when used early in high-risk people but, as one would expect for an antiviral, much less success when used late in the disease course. Even so, it has demonstrated significant benefit in large hospital studies in Michigan and New York City when started within the first 24 to 48 hours after admission.
In fact, as inexpensive, oral and widely available medications, and a nutritional supplement, the combination of hydroxychloroquine, azithromycin or doxycycline, and zinc are well-suited for early treatment in the outpatient setting. The combination should be prescribed in high-risk patients immediately upon clinical suspicion of COVID-19 disease, without waiting for results of testing. Delays in waiting before starting the medications can reduce their efficacy.
Third, concerns have been raised by the FDA and others about risks of cardiac arrhythmia, especially when hydroxychloroquine is given in combination with azithromycin. The FDA based its comments on data in its FDA Adverse Event Reporting System. This reporting system captured up to a thousand cases of arrhythmias attributed to hydroxychloroquine use. In fact, the number is likely higher than that, since the reporting system, which requires physicians or patients to initiate contact with the FDA, appreciably undercounts drug side effects.
But what the FDA did not announce is that these adverse events were generated from tens of millions of patient uses of hydroxychloroquine for long periods of time, often for the chronic treatment of lupus or rheumatoid arthritis. Even if the true rates of arrhythmia are ten-fold higher than those reported, the harms would be minuscule compared to the mortality occurring right now in inadequately treated high-risk COVID-19 patients. This fact is proven by an Oxford University study of more than 320,000 older patients taking both hydroxychloroquine and azithromycin, who had arrhythmia excess death rates of less than 9/100,000 users, as I discuss in my May 27 paper cited above. A new paper in the American Journal of Medicine by established cardiologists around the world fully agrees with this.
In the future, I believe this misbegotten episode regarding hydroxychloroquine will be studied by sociologists of medicine as a classic example of how extra-scientific factors overrode clear-cut medical evidence. But for now, reality demands a clear, scientific eye on the evidence and where it points. For the sake of high-risk patients, for the sake of our parents and grandparents, for the sake of the unemployed, for our economy and for our polity, especially those disproportionally affected, we must start treating immediately.
Harvey A. Risch, MD, PhD, is professor of epidemiology at Yale School of Public Health.
The views expressd in this article are the writer's own.


נא_שכל
שר חמשת אלפים
תגובות: 5801
זיך איינגעשריבען אום: מאנטאג יולי 14, 2008 10:44 pm
לאקאציע: עולם הדמיון

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך נא_שכל » מאנטאג יולי 27, 2020 3:50 pm

wow!

וואס טוט זיך יעצט אין א"י, נוצט מען עס?
"ואומר לאשר יבוא מכתבי לחזות, אכול את המגילה הזאת. כי מהאוכל יצא מאכל, ושכל יצא משכל ..." (ר' ברכיה בן נטרונאי הנקדן, בהקדמת ספרו 'משלי שועלים').

אוועטאר
מומחה יוחס
שר ארבעת האלפים
תגובות: 4253
זיך איינגעשריבען אום: זונטאג אפריל 11, 2010 1:22 pm
לאקאציע: דא אינעווייניג

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך מומחה יוחס » מאנטאג יולי 27, 2020 3:51 pm

אין אר''י ניצט מען דער רעדמעסווער אין נישט דאס...
איך בין די פרעזידענט אין אמעריקא

קאנטרי
שר מאה
תגובות: 207
זיך איינגעשריבען אום: מאנטאג סעפטעמבער 02, 2019 9:45 pm

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך קאנטרי » מאנטאג יולי 27, 2020 6:30 pm

ער גייט ארויסקומען מיט א סטאדי 99.3 זענען געראטעוועט דורך זעלענקא און נאך דוקטוירים

KMW
שר האלף
תגובות: 1650
זיך איינגעשריבען אום: דאנארשטאג פאברואר 23, 2017 11:05 am

Re: Hydroxychloroquine רפואה פאר COVID-19

תגובהדורך KMW » מאנטאג יולי 27, 2020 10:14 pm

hydroxychloroquine העלפט, אלעס איז פאליטיק
הײנט אין װאשינגטאן פרעס קאנפערענס

BREAKING: American Doctors Address COVID-19 Misinformation with SCOTUS Press Conference


https://www.google.com/search?q=BREAKIN ... 20&bih=937


צוריק צו “קאראנא וויירוס”

ווער איז אונליין

באנוצערס וואס דרייען זיך דא: PetalBot, בארג און 7 געסט